Back HCV Disease Progression Transplant/Artificial Liver

Liver Transplant - HCV

EASL 2010: MARS and Prometheus Artificial Liver Devices Offer Some Benefits for Patients with Liver Failure, but Did Not Improve Survival

An out-of-body liver dialysis device known as the Molecular Adsorbents Recirculating System (MARS) -- which takes over some lost filtering function in people with liver failure -- reduced levels of toxic substances in the blood and improved symptoms of hepatic encephalopathy in patients with acute-on-chronic liver failure, though it did not significantly extend survival, according to a late-breaker presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) this month in Vienna. Another study found that the Prometheus extracorporeal liver support system also did not improve survival overall, though it did help specific groups of patients.

Read more:

Liver Transplant Do Not Impair Immune Response in HIV/HCV Coinfected Patients

HIV/HCV coinfected patients who undergo liver transplantation do not lose immune responses to hepatitis C virus (HCV), HIV, or opportunistic infections, according to an analysis reported in the December 2009 Journal of Hepatology. This study adds to the evidence that appropriately selected coinfected individuals can be suitable candidates for liver transplants.

Read more:

AASLD 2009: Study Looks at Factors Affecting Survival of HIV/HCV Coinfected Liver Transplant Recipients

While HIV/HCV coinfected patients can have good outcomes after liver transplantation, acute organ rejection remains a risk factor and survival does not match that of HIV negative people with hepatitis C virus (HCV) alone, according to a study presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) this month in Boston.

Read more:

African Americans with Hepatitis C Have Worse Outcomes than White Patients after Liver Transplantation

African-American individuals who undergo liver transplants due to complications of hepatitis C virus (HCV) infection experience more rapid post-transplant fibrosis progression and histological inflammation compared with white patients, even though they tend to experience slower pre-transplant disease progression, according to a study presented at the recent 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) in Boston.

Read more:

Older Donor Liver Grafts May Be Suitable for Chronic Hepatitis C Patients Requiring Transplantation

Liver transplantation is the only effective treatment for end-stage liver failure due to chronic hepatitis C virus (HCV) infection, but the availability of the procedure is severely hampered by the shortage of donor organs. Surgeons have traditionally preferred to use livers from young donors, but increasing the age of acceptable donors could significantly expand the available liver supply. 

Read more: